Sotera Health (NASDAQ:SHC) Coverage Initiated at The Goldman Sachs Group

Investment analysts at The Goldman Sachs Group started coverage on shares of Sotera Health (NASDAQ:SHC) in a report released on Friday,Briefing.com Automated Import reports. The brokerage set a “neutral” rating and a $14.00 price target on the stock. The Goldman Sachs Group’s target price would suggest a potential upside of 7.90% from the stock’s previous close.

Several other analysts have also issued reports on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $17.00 price target on shares of Sotera Health in a research report on Thursday, November 21st. Citigroup boosted their target price on shares of Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $16.08.

Sotera Health Trading Down 2.3 %

NASDAQ:SHC opened at $12.98 on Friday. Sotera Health has a 12 month low of $10.71 and a 12 month high of $17.44. The company has a current ratio of 2.88, a quick ratio of 2.61 and a debt-to-equity ratio of 4.91. The firm’s 50 day moving average is $14.96 and its 200 day moving average is $14.06. The stock has a market capitalization of $3.68 billion, a PE ratio of 51.90 and a beta of 1.96.

Sotera Health (NASDAQ:SHC) last issued its earnings results on Tuesday, November 5th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The firm had revenue of $285.47 million during the quarter, compared to the consensus estimate of $278.64 million. During the same quarter in the previous year, the firm earned $0.18 earnings per share. The business’s quarterly revenue was up 8.5% compared to the same quarter last year. Sell-side analysts expect that Sotera Health will post 0.61 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Sanctuary Advisors LLC boosted its position in shares of Sotera Health by 154.4% during the 3rd quarter. Sanctuary Advisors LLC now owns 29,088 shares of the company’s stock valued at $486,000 after acquiring an additional 17,652 shares during the last quarter. Neo Ivy Capital Management bought a new stake in Sotera Health during the third quarter valued at approximately $720,000. Geode Capital Management LLC grew its stake in Sotera Health by 19.4% in the 3rd quarter. Geode Capital Management LLC now owns 2,755,391 shares of the company’s stock worth $46,026,000 after buying an additional 447,186 shares in the last quarter. Barclays PLC increased its holdings in shares of Sotera Health by 169.8% in the 3rd quarter. Barclays PLC now owns 473,597 shares of the company’s stock worth $7,909,000 after buying an additional 298,085 shares during the last quarter. Finally, Public Employees Retirement System of Ohio increased its holdings in shares of Sotera Health by 14.3% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 54,706 shares of the company’s stock worth $914,000 after buying an additional 6,826 shares during the last quarter. Institutional investors own 91.03% of the company’s stock.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.